TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

NCT07502872 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma
High-grade B-cell Lymphoma
Lymphoma
Lymphoma, B-Cell

Interventions

DRUG: Tafasitamab
DRUG: Polatuzumab vedotin
DRUG: Glofitamab
DRUG: Obinutuzumab

Sponsor

Brown University

Collaborators

[object Object]
[object Object]
[object Object]